SCHEMBL24513989

SCHEMBL24513989

CC(C)CCCOCCOCCNCc1ccc(N2CCN(C(C)C)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ PKM P14618 1/20 0.41
▸ HRH3 Q9Y5N1 5/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ RAD52 P43351 1/20 0.35
▸ PAX8 Q06710 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.34
▸ THRB P10828 1/20 0.34
▸ ESRRB O95718 2/20 0.34
▸ ESRRG P62508 2/20 0.34
▸ NCF1 P14598 1/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRD1 P41143 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25110212 0.94 KDM4E (0.42) KDM4EALDH1A1MAPTPKMHRH3
SCHEMBL24513990 0.91 KDM4E (0.41) KDM4EALDH1A1MAPTPKMHRH3
SCHEMBL22793929 0.90 KDM4E (0.42) KDM4EALDH1A1MAPTPKMHRH3
SCHEMBL22790760 0.89 L3MBTL1 (0.35) KDM4EALDH1A1MAPTL3MBTL1RAD52
SCHEMBL22793930 0.88 KDM4E (0.43) KDM4EALDH1A1MAPTPKMHRH3
SCHEMBL25481170 0.88 KDM4E (0.34) KDM4EALDH1A1MAPTHRH3L3MBTL1
SCHEMBL25108924 0.88 KDM4E (0.40) KDM4EALDH1A1MAPTL3MBTL1RAD52
SCHEMBL25481136 0.85 L3MBTL1 (0.34) KDM4EALDH1A1MAPTL3MBTL1RAD52
SCHEMBL25109776 0.83 HRH3 (0.46) KDM4EALDH1A1MAPTPKMHRH3
SCHEMBL22790759 0.83 KDM4E (0.42) KDM4EALDH1A1MAPTPKMHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
WO-2022125804-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 KDM4E 624/4885ALDH1A1 3736/4885MAPT 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback